Mersana Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview

Mersana Therapeutics

13/05/2025 15:24

Mersana Therapeutics Inc MRSN.OQ MRSN.O is expected to show a fall in quarterly revenue when it reports  results on May 15 for the period ending March 31 2025

The Cambridge Massachusetts-based  company is expected to report a 36.8% decrease in revenue to $5.84 million from $9.25 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Mersana Therapeutics Inc is for a loss of 19 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 0.9% in the last three months. ​

Wall Street's median 12-month price target for Mersana Therapeutics Inc is $5.00​, above​ its last closing price of $0.36. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.16
-0.16
-0.11
Beat
31.7
Sep. 30 2024
-0.18
-0.18
-0.09
Beat
48.7
Jun. 30 2024
-0.17
-0.17
-0.20
Missed
-16.7​
Mar. 31 2024
-0.18
-0.18
-0.16
Beat
11.6
​​Dec. 31 2023
-0.12
-0.16
-0.16
Met
2.6
Sep. 30 2023
-0.35
-0.36
-0.27
Beat
25.4​
Jun. 30 2023
-0.37
-0.44
-0.47
Missed
-6.5
Mar. 31 2023
-0.40
-0.44
-0.52
Missed
-19.3

This summary was machine generated May 13 at 14:24 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)